Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
Disclosed is a benzyl-oxathiazine derivative, as shown in Formula I, the derivative being substituted with adamantane or noradamantane: the variables of which are as described herein; also disclosed is a method of preparation and use of same.
1. A compound of the formula I
in which
R1 is
wherein the R1 radical is bonded as shown in formula Ia or formula Ib below:
R2 is H, F, (C 1 -C 3 )-alkyl where the alkyl radical may be mono- to trisubstituted by fluorine;
R3, R4, R5, R13 are each independently
H, F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , —(C 1 -C 6 )-alkylene-(R9), O—(C 1 -C 6 )-alkylene-(R9), tert-butyl, isopropylene-(R9), (C═O)—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkylene-R9) 2 , (C 1 -C 6 )-alkylene-NH 2 , (C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-R9) 2 , —O—(C 1 -C 6 )-alkylene-NH 2 , —O—(C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-(R9), —O—(C 1 -C 6 )-alkylene-N((C 1 -C 6 )-alkylene-R9) 2 , —NH—(C 1 -C 6 )-alkylene-NH 2 , —NH—(C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-(R9), —NH—(C 1 -C 6 )-alkylene-N((C 1 -C 6 )-alkylene-R9) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
(C 6 -C 10 )-aryl, —(C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl,
where the aryl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 , (C 6 -C 10 )-aryl, (C 3 -C 7 )-cycloalkyl, 4- to 12-membered heterocycle;
where the (C 6 -C 10 )-aryl radical, (C 3 -C 7 )-cycloalkyl radical, 4- to 12-membered heterocycle radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
4- to 12-membered heterocycle, —(C 1 -C 6 )-alkylene-4- to −12-membered heterocycle,
where the heterocyclyl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkyl) 2 , SO 2 —(C 1 -C 6 )-alkylene-(R9), SO 2 —C 2 H 2 F 3 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkylene-(R9), SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkylene-(R9), CONH 2 , CONH(C 1 -C 6 )-alkylene-(R9), CON((C 1 -C 6 )-alkyl) 2 , SF 5 , (C 6 -C 10 )-aryl, (C 3 -C 7 )-cycloalkyl, 4- to 12-membered heterocycle;
where the (C 6 -C 10 )-aryl radical, (C 3 -C 7 )-cycloalkyl radical, 4- to 12-membered heterocycle radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
R7, R8 are each independently H, (C 1 -C 3 )-alkyl, where the alkyl radical may be mono- to trisubstituted by fluorine, or R7 and R8 together with the carbon atom to which they are bonded form a 3-7-membered carbocycle or heterocycle;
R9 is H, OH, OCH 3 , OCF 3 , CHF 2 , CF 3 ;
R10 is H, CONH 2 ;
and pharmaceutically compatible salts thereof.
2. The compound of claim 1 , wherein
R1 is
wherein the R1 radical is bonded as shown in the formula Ia or the formula Ib;
R2 is H, (C 1 -C 3 )-alkyl;
R3, R4, R5, R13 are each independently
H, F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , —(C 1 -C 6 )-alkylene-(R9), O—(C 1 -C 6 )-alkylene-(R9), tert-butyl, isopropylene-(R9), (C═O)—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkylene-R9) 2 , (C 1 -C 6 )-alkylene-NH 2 , (C 1 -C 6 )-alkylene-NH(C 1 -C 6 )—alkylene-(R9), (C 1 -C 6 )-alkylene-N((C 1 -C 6 )-alkylene-R9) 2 , —O—(C 1 -C 6 )-alkylene-NH 2 , —O—(C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-(R9), —O—(C 1 -C 6 )-alkylene-N((C 1 -C 6 )-alkylene-R9) 2 , —NH—(C 1 -C 6 )-alkylene-NH 2 , —NH—(C 1 -C 6 )-alkylene-NH(C 1 -C 6 )-alkylene-(R9), —NH—(C 1 -C 6 )-alkylene-N((C 1 -C 6 )-alkylene-R9) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
(C 1-6 —C 10 )-aryl, —(C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl,
where the aryl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 , (C 6 -C 10 )-aryl, (C 3 -C 7 )-cycloalkyl, 4- to 12-membered heterocycle;
where the (C 6 -C 10 )-aryl radical, (C 3 -C 7 )-cycloalkyl radical, 4- to 12-membered heterocycle radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
4- to 12-membered heterocycle, —(C 1 -C 6 )-alkylene-4- to −12-membered heterocycle,
where the heterocyclyl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkyl) 2 , SO 2 —(C 1 -C 6 )-alkylene-(R9), SO 2 —C 2 H 2 F 3 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkylene-(R9), SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkylene-(R9), CONH 2 , CONH(C 1 -C 6 )-alkylene-(R9), CON((C 1 -C 6 )-alkyl) 2 , SF 5 , (C 6 -C 10 )-aryl, (C 3 -C 7 )-cycloalkyl, 4- to 12-membered heterocycle;
where the (C 6 -C 10 )-aryl radical, (C 3 -C 7 )-cycloalkyl radical, 4- to 12-membered heterocycle radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
R7, R8 are each independently H, (C 1 -C 3 )-alkyl;
R9 is H, OH, OCH 3 , OCF 3 , CHF 2 , CF 3 ;
R10 is H, CONH 2 ;
and pharmaceutically compatible salts thereof.
3. The compound of claim 1 , wherein
R1 is
wherein the R1 radical is bonded as shown in the formula Ia or the formula Ib;
R2 is H;
R3, R4, R5, R13 are each independently
H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , OCHF 2 , —(C 1 -C 6 )-alkylene, —O—(C 1 -C 6 )-alkylene;
(C 6 -C 10 )-aryl,
where the aryl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkyl, SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
4- to 12-membered heterocycle,
where the heterocyclyl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkyl) 2 , SO 2 —(C 1 -C 6 )-alkylene-(R9), SO 2 —C 2 H 2 F 3 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkylene-(R9), SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkylene-(R9), CONH 2 , CONH(C 1 -C 6 )-alkylene-(R9), CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
R7, R8 is H, (C 1 -C 3 )-alkyl;
R9 is H, OH, OCH 3 , OCF 3 , CHF 2 , CF 3 ;
R10 is H, CONH 2 ;
and pharmaceutically compatible salts thereof.
4. The compound of claim 1 , wherein
R1 is
wherein the R1 radical is bonded as shown in the formula Ib;
R2 is H;
R3, R4, R5 are each independently
H, F, CI, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , OCHF 2 , —(C 1 -C 6 )-alkylene, —O—(C 1 -C 6 )-alkylene;
R13 is F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , OCHF 2 , —(C 1 -C 6 )-alkylene, —O—(C 1 -C 6 )-alkylene;
azetidinyl,
where the azetidinyl radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , OCHF 2 , O—(C 1 -C 6 )-alkylene-(R9), (C 1 -C 6 )-alkylene-(R9), NH 2 , NH(C 1 -C 6 )-alkylene-(R9), N((C 1 -C 6 )-alkyl) 2 , SO 2 —(C 1 -C 6 )-alkylene-(R9), SO 2 —C 2 H 2 F 3 , SO 2 —CH 3 , SO 2 —NH 2 , SO 2 —NH(C 1 -C 6 )-alkylene-(R9), SO 2 —N((C 1 -C 6 )-alkyl) 2 , COOH, COO—(C 1 -C 6 )-alkylene-(R9), CONH 2 , CONH(C 1 -C 6 )-alkylene-(R9), CON((C 1 -C 6 )-alkyl) 2 , SF 5 ;
R7, R8 is H, (C 1 -C 3 )-alkyl;
R9 is H, OH, OCH 3 , OCF 3 , CHF 2 , CF 3 ;
R10 is H, CONH 2 ;
and pharmaceutically compatible salts thereof.
5. A pharmaceutical composition comprising the compound of claim 1 , or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier and/or excipient.
6. The pharmaceutical composition of claim 5 , further comprising at least one further active ingredient.
7. The pharmaceutical composition of claim 6 , wherein said active ingredient is one or more antidiabetics, active hypoglycemic ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, PPAR delta agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, HM74A receptor agonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, glycogen phosphorylase inhibitors, glucagon receptor antagonists, activators of glucokinase, inhibitors of gluconeogenesis, inhibitors of fructose 1,6-biphosphatase, modulators of glucose transporter 4, inhibitors of glutamine:fructose-6-phosphate amidotransferase, inhibitors of dipeptidylpeptidase IV, inhibitors of 11-beta-hydroxysteroid dehydrogenase 1, inhibitors of protein tyrosine phosphatase 1B, modulators of the sodium-dependent glucose transporter 1 or 2, GPR40 modulators, inhibitors of hormone-sensitive lipase, inhibitors of acetyl-CoA carboxylase, inhibitors of phosphoenolpyruvate carboxykinase, inhibitors of glycogen synthase kinase-3 beta, inhibitors of protein kinase C beta, endothelin-A receptor antagonists, inhibitors of I kappaB kinase, modulators of the glucocorticoid receptor, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, CB1 receptor antagonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA agonists, lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR β agonists or amphetamines.
8. A process for preparing a pharmaceutical composition comprising mixing the compound of claim 1 with a pharmaceutically suitable carrier and converting said mixture to a form suitable for administration.
9. A method of treating hyperglycemia, comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 5 .
10. A method of treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 5 .
11. A method of treating insulin resistance, comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 5 .
12. A kit consisting of separate packages of
a) an effective amount of the compound of claim 1 and
b) an effective amount of a further active medicament ingredient.